BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jun 29, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Cimzia certolizumab pegol regulatory update

EMEA's CHMP issued a positive opinion on an MAA from UCB for Cimzia certolizumab pegol to treat moderately to severely active rheumatoid arthritis in adults. Last month, FDA...

Read the full 120 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >